




FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU3517USW		SERIAL NO. 10/070,084	
				APPLICANT Andrews et al.			
				FILING DATE 03/01/02		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AC	5,945,450	31 Aug. 1999	Takenouchi, et. al.			
	AD	5,719,143	17 Feb. 1998	Badore, et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	BC	EP 0667344A1	13 Feb. 1995	EPO			English abstract
	BD	WO 93/15043	8 May 1993	PCT			English abstract
	BE	JP 59 181246	1984-10-15	JP			English abstract
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	CE	De Clercq, "Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection," Il Farmco, 1999, Vol. 54, pgs 26-45.					
	CF	Balzarini, "Suppression of Resistance to Drugs Targeted to Human Immunodeficiency Virus Reverse Transcriptase by Combination Therapy," Biochemical-Pharmacology, 1999, Vol. 58; p. 1-					
	CG	Inaba, et. al., "Benzodiazepines. V. A Novel Synthesis of a 7-Nitro-1,4-benzodiazepine Derivative," Chem. Pharm. Bull., 1971, Vol. 19, p. 722.					
Continue on page _____							
EXAMINER						DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP-§ 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrews et al.

Serial No.: 10/070,084 ✓

Group Art Unit: 1614

Filed: March 1, 2002

Examiner: ✓

For: Benzophenones as Inhibitors of Reverse Transcriptase ✓

Commissioner for Patents
Washington, D.C. 20231TECH CENTER 160012900
JAN 24 2003# 9
9/29/03
82W
RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ [X] Copies of the references are enclosed: AC, BC-BE, CE-CG
☐ [] Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
☐ [] A copy of the International Search Report, which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- B. ☐ [] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
 (2) a notice of allowance under § 1.311,

whichever occurs first.

- ☐ [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).


- C. ☐ [] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No. _____
 In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Karen L. Prus
Registration No. 39,337

Date:

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709

Telephone: (919) 483-2192

Facsimile: (919) 483-7988

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): **Andrews et al.**

1614
Docket No.

PU3517USW

Serial No.

10/070,084

Filing Date

March 1, 2002

JAN 22 2003

Examiner

Group Art Unit

1614

Invention: **Benzophenones as Inhibitors of Reverse Transcription**

I hereby certify that this **Supplemental Information Disclosure with accompanying papers**

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Commissioner of Patents and Trademarks, Washington, D.C. 20231-0001 on

Jan. 16, 2003

(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

Valerie L. Phillips

(Signature of Person Mailing Correspondence)